Advanced Search

Publications > Journals > Journal of Clinical and Translational Hepatology > Article Full Text


Non-Hodgkin Lymphoma of the Liver: A US Population-based Analysis

  • Mohamed Abd El-Fattah*
 Author information
Journal of Clinical and Translational Hepatology   2017;5(2):83-91

doi: 10.14218/JCTH.2017.00015


Background and Aims: Non-Hodgkin lymphoma (NHL) of the liver is a rare lymphoid malignancy, accounting for less than 1% of extranodal lymphomas.

Methods: I conducted an analysis of the U.S Surveillance, Epidemiology, and End Results (SEER) database to evaluate the histological subtypes and the survival outcomes of 785 cases with hepatic NHL between 1973 and 2012.

Results: There were 785 of 312 459 cases with NHL had a first primary hepatic NHL (0.25%). Of the total 785 cases, the median age at diagnosis was 61 years (range 3–95 years) and male-female ratio of 1.7:1. The most common subtype was diffuse large B cell lymphoma (63.2%). In all patients, the median overall survival (OS) was 33 months (95%CI, 22–48 months). The 5-year OS rate for indolent B-cell NHLs was 62%, compared with 44% for an aggressive B-cell NHLs and 42% for T-cell NHLs. The median OS improved from 19 months in patients diagnosed in a period 1996–2000 to 60 months when diagnosed between 2006 and 2012 (p < .001). In a multivariable Cox regression analysis, the age ≥80 years (adjusted hazard ratio [aHR] 3.21, p < .001), male gender (aHR 1.26, p = .02), Black race (aHR, 1.70, p < .001), and T-cell NHL variants (aHR 1.73, p = .03) were unfavourable prognostic factors.

Conclusion: NHL of the liver comprises about 0.3% of all NHLs and survival was improved in the recent calendar period.


Non-Hodgkin lymphoma, Liver, Primary hepatic lymphoma, Hepatic neoplasms


Non-Hodgkin lymphoma (NHL) is the sixth leading cause of new cancer cases among men and the fifth among women, accounting for 3% to 4% of cancer-related deaths in the United States.1 Approximately 25% to 40% of NHL patients present with an extranodal lymphoma.2 Although liver contains lymphoid tissue, host factors seem to make the liver a poor environment for the development of malignant lymphomas. NHL is more likely than Hodgkin lymphoma to have hepatic involvement.3 The prevalence of liver involvement by NHL is reported to be 15% to 30%, and more than 50% in necropsy studies.3–8

Primary hepatic lymphoma (PHL) is a lymphoma limited to the liver or having major liver involvement without evidence of extrahepatic involvement (e.g., no spleen, lymph nodes, bone marrow, peripheral blood, or other lymphoid structures) for at least 6 months.7 PHL represents 0.4% of extranodal NHLs and 0.016% of all NHLs.7,8 Based on liver infiltration, PHL can be subdivided into uninodular (39–42%), multinodular (50–55%), and diffuse (6–8%) types.6,9 Diffuse liver involvement of PHL is usually observed in immuno-compromised patients,10 such as human immunodeficiency virus (HIV) or liver diseases.11 Among 205 liver biopsies with lymphoma, 45% was diffuse large B cell lymphoma (DLBCL), and 12% was T cell lymphoma.12

Chronic antigen stimulation by viral infection (HIV, hepatitis C virus (HCV), hepatitis B virus (HBV) and Epstein-Barr virus (EBV), liver cirrhosis, immunosuppressive therapy and autoimmune disease are implied to have an etiological relevance to the development of PHL.8 HCV is found in 10% to 60% of patients with PHL,6,9,13,14 with geographic variations, and these patients have aggressive histological subtypes.9,15 Most PHL of HCV-positive patients were of B cell origin, and T cell type PHL has been rarely reported.15 It seems that PHL outcomes are not affected by presence of HCV infection6 and regress with HCV eradication.16 Furthermore, HIV was reported in 40% to 75% of PHL cases,10,14 and these patients have a worse prognosis.11

PHL most commonly affects men during their fifth decade of life, and has a male-to-female ratio of 2–3:1.3,8,17 Liver biopsy is the most valuable tool for diagnosis.10,14 Clinical presentation of PHL is nonspecific and includes such symptoms as fever, loss of weight, night sweats, abdominal pain, jaundice and hepatomegaly. Incidental identification has been documented in 10% of PHL cases.18 Acute liver failure reportedly accounts for 4.5% of PHL presentations,8 and about 3% of reported acute liver failure was related to hepatic lymphoma,19 notably of diffuse pattern.20 Most cases of acute liver failure from lymphoma are diagnosed on autopsy, with an average survival of 11 days from diagnosis.21 PHL patients have abnormal liver function tests, with elevation of lactate dehydrogenase and alkaline phosphatase. Alpha-fetoprotein and carcinoembryonic antigen are normal in almost all cases, and hypercalcemia was observed in 40% of cases,6 being related to release of calcitriol by malignant lymphoma cells.22

Radiologically, PHL lesions on ultrasound are hypoechoic, and on computed tomography are hypoattenuating with intravenous rim enhancement.23,24 On magnetic resonance imaging (MRI), the lesions show hypointensity on T1-weighted images and hyperintensity on T2-weighted images.24

Approximately 80% of the reported cases with PHL have been of the B cell type (mainly DLBCL), whereas the remaining cases have been of the T cell type.5,17 Patients with hepatic DLBCL tend to be HCV-positive and have a diffuse liver infiltration with a poor prognosis.25 T cell lymphoma of the liver accounted for 5–10% of PHL patients,3 and these patients have shown an aggressive clinical course,26 and are mainly of the Asian population.27

Therapeutic management of PHL is based on surgery, chemotherapy and radiotherapy. However, 14% of cases are inappropriate for therapy due to comorbidity or poor performance.14 With chemotherapy, the reported survival ranges from 3.7 to 30 months,8 and liver transplantation is favorable.20 The 5-year overall survival (OS) of treated patients with PHL6 is comparable to that of hepatocellular carcinoma patients who undergo liver transplantation.28 Prognosis of PHL depends on NHL subtype, type of liver involvement (nodular or diffuse),11 therapeutic modalities (chemotherapy, surgery or radiotherapy),18 HIV status5 and liver disease.9

The aim of this retrospective study was to assess the clinical characteristics, subtypes and outcomes of NHL affecting the liver. To date, fewer than 400 PHL cases have been reported in the worldwide literature3,7,8,18,21,25,29–31 and large case series.6,9,10,14,32


Data source

The Surveillance Epidemiology and End Results (SEER) program of the U.S National Cancer Institute collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 30% of the US population (www.seer.cancer.gov ). The SEER database includes cancer registries in the following areas; Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound, Utah, Los Angeles, San Jose-Monterey, Rural Georgia, the Alaska Native Tumor Registry, Greater California, Kentucky, Louisiana, New Jersey, and Greater Georgia.

Study population

Hepatic NHL in the SEER cancer registry (1973 to 2012) was defined by cancer diagnosis in anatomic site of liver by International Classification of Diseases, 3rd edition codes (ICD-O-3 code, C22.0) and NHL morphologies (9590–9595 and 9670–9723). For this study, I used the same variable selection approach of O’Neill et al.33 for NHL of the central nervous system in the SEER database study. As shown in Fig. 1, I restricted analysis to the patients who had microscopic confirmation of their disease (tissue histology or cytology). In an attempt to assure that only first primary NHLs were included in the analysis, I excluded patients who had a prior, or a concurrent diagnosis of other cancers. I also excluded patients diagnosed by autopsy or death certificate, and who had a survival time of 0 months. The few patients who had incomplete data regarding radiation or surgery were not included in the analysis. The final cohort included (Fig. 1) 785 patients with hepatic lymphoma (HEL) grouped into categories according to cell origin and clinical aggressiveness as follows: (1) aggressive B cell NHLs (DLBCL and Burkitt’s lymphoma); (2) Indolent B cell NHLs (follicular lymphoma; small B cell lymphocytic lymphoma and marginal zone B cell lymphoma), (3) T cell NHLs (mature T cell lymphoma and anaplastic large cell lymphoma, T cell and null cell type); (4) NHL– not otherwise specified [NHL-NOS]; and (5) other rare subtypes. Age was categorized into 5 age groups of <50, 50–59, 60–69, 70–79, and ≥80 years. Race was categorized as White, Black, Asian and Others. The cohort was divided into 4 according to the year of diagnosis (1973–1995, 1996–2000, 2001–2005, and 2006–2012). HIV-related deaths were identified in the SEER by variable ‘cause of death to SEER site recode’ (code 50040).

Flow diagram of patient selection within the SEER database during 1973–2012.
Fig. 1.  Flow diagram of patient selection within the SEER database during 1973–2012.

Abbreviation: ICD, International Classification of Diseases for Oncology.

Statistical analysis

The clinical and demographic characteristics were expressed as proportion (%) and frequency (n) for categorical variables, or as median and range for continuous variables. The primary endpoint of the study was OS, which was defined as the interval between the date of diagnosis of HEL to the date of death from any cause (follow-up to obtain vital status) or date of last follow-up. The estimated median follow-up was determined using the inverse Kaplan–Meier method. Kaplan-Meier curves and multivariable Cox model were built to analyze the OS and prognostic factors. I performed all statistical analyses by use of STATA, version 12 (STAT Corp, College Station, Texas, USA). All p values were two-sided, and p < 0.05 suggested statistical significance.


Clinical characteristics of all patients

In the SEER database, between 1973 and 2012, there were 362,697 cases with lymphoma (NHL = 312,459; Hodgkin lymphoma = 50,238). Of the total 312,459 NHL cases, there were 215,072 cases (68.8%) with nodal NHL, and 97,387 cases with extranodal NHL (31.2%). Out of 97,387 cases with extranodal NHL, there were 1,325 cases (1.3%) with hepatic NHL. The final cohort included 785 cases with a first primary NHL of the liver (HEL) after applying my exclusion criteria (Fig. 1), that represented 0.25% of all NHLs. The clinical features of the 785 patients with HEL are presented in Table 1. Of the 785 eligible cases, the median age at diagnosis was 61 years (range, 3–95 years) and 33.5% were equal or older than 70 years. Most of the patients were male (64.2%) and Whites (82.3%).

Table 1.

Patient characteristics by histologic subtype

Histologyn (%)Median age, years (Range)Male, n (%)Overall survival
Median OS5–year OS
All patients785 (100.0)61 (3–95)504 (64.2)33.044
DLBCL496 (63.2)62 (3–95)328 (66.1)28.143
SLL14 (1.8)67 (41–81)10 (71.4)5342
MZL23 (2.9)68 (44–87)11 (47.8)82.960
Follicular lymphoma22 (2.8)64.5 (41–81)9 (40.9)NR84
Burkitt’s lymphoma25 (3.2)36 (5–87)19 (76.0)NR55
T cell lymphoma27 (3.4)52 (25–90)21 (77.8)8.342
NHL-NOS155 (19.7)58 (11–91)96 (61.9)21.243
Others23 (2.9)60 (21–88)10 (43.5)8.325

Histologic subtypes

The clinical characteristics of the various subtypes of HEL are presented in Tables 1 and 2. According to lymphoma cell origin and clinical aggressiveness, there were 521 (66.4%) cases of aggressive B cell NHLs, 59 (7.5%) indolent B cell NHLs and 27 (3.4%) T cell NHLs. The most common subtypes identified were DLBCL (n = 496, 63.2%) and NHL-NOS (n = 155, 19.7%). The next most common subtypes were T cell lymphomas (3.4%), Burkitt’s lymphoma (3.2%), follicular lymphoma (2.8%), marginal zone B cell lymphoma (MZL) (2.9%) and small B cell lymphocytic lymphoma (SLL) (1.8%). The subtypes of T cell NHL were mature T cell lymphoma-NOS (n = 16), anaplastic large cell lymphoma, T cell and null cell type (n = 9), NK/T cell lymphoma, nasal and nasal-type (n = 1), and precursor T cell lymphoblastic lymphoma (n = 1). All of the HEL subtypes were found more frequently in male patients, except for MZL (47.8%) and follicular lymphoma (40.9%). Although the median age for all patients was 61 years, Burkitt’s lymphoma patients had a much younger median age (36 years; range, 5–87 years). The frequency of aggressive T cell NHLs was higher in Asians (8.7%) and Blacks (6.0%) than in Whites (2.8%).

Table 2.

Patient characteristics by cell origin and tumor behavior

Histologyn (%)Median age, years (Range)Male, n (%)Death, n (%)Median OS
Aggressive B cell NHLa521 (66.4)62 (3–95)347 (66.6)312 (59.9)31.2
Indolent B cell NHLb59 (7.5)66 (41–87)30 (50.8)23 (39.0)152.4
T cell NHL27 (3.4)52 (25–90)21 (77.8)16 (59.3)8.3
NHL-NOS155 (19.7)58 (11–91)96 (61.9)105 (67.7)21.2
Others23 (2.9)60 (21–88)10 (43.5)18 (78.3)8.3


With a median follow-up of 87 months (95%CI: 79 to 100 months), 474 (60.4%) patients had died by the end of study. Of which, 256 patients (54%) died due to NHL, and 80 patients (16.9%) due to HIV-related complications. HIV-related deaths accounted for 16.2% of deaths of DLBCL, and 40% of deaths of Burkitt’s lymphoma (data not shown).

Survival and prognostic variables

For the entire cohort, with a median OS of 33 months (95% confidence interval [CI]: 22–48 months), the estimated 1-, 3-, 5-, 10- and 20-year OS rates were 59% (95%CI: 56–62%), 49% (95%CI: 46–53%), 44% (95%CI: 41–48), 35% (95%CI: 32–39%) and 21% (95%CI: 15–27%), respectively. Compared to patients aged <50 years, the hazards of mortality of 60–69 years age group, 70–79 years age group and ≥80 years age group were 1.61-fold (p < 0.001), 1.8-fold (p < 0.001) and 3.2-fold (p < 0.001), respectively (Fig. 2). Males had a shorter 5-year OS than females (41% vs. 50%), and risk of death in males was 26% higher than in females (adjusted hazard ratio [aHR]: 1.26, 95%CI: 1.03–1.54, p = 0.02). The OS was lower in Blacks (aHR: 1.70, 95%CI: 1.26–2.29, p < 0.001) and Asians (aHR: 1.57, 95% CI: 1.10–2.25, p = 0.01) compared with White patients (Table 3, Fig. 3).

Kaplan–Meier estimate of overall survival by age groups.
Fig. 2.  Kaplan–Meier estimate of overall survival by age groups.

Abbreviations: OS, overall survival; 95%CI, confidence interval; aHR, adjusted hazard ratio.

Table 3.

Clinical features, outcomes and prognostic factors of non-Hodgkin lymphoma of the liver

Variablesn (%)Median OS in monthsMultivariate analysis
Hazard ratio (95%CI)p–value
All patients785 (100.0)33.0
Age in years
 <50240 (30.6)58.0Ref
 50–59137 (17.5)119.31.10 (0.81–1.50)0.53
 60–69145 (18.5)28.31.61 (1.22–2.13)<0.001
 70–79158 (20.1)28.31.88 (1.43–2.48)<0.001
 +80105 (13.4)9.023.21 (2.37–4.35)<0.001
 Female281 (35.8)60.1Ref
 Male504 (64.2)24.41.26 (1.03–1.54)0.02
 White646 (82.3)39.3Ref
 Black83 (10.6)11.91.70 (1.26–2.29)<.001
 Asian46 (5.9)6.91.57 (1.10–2.25)0.01
 Othersa10 (1.3)66.10.97 (0.43–2.19)0.94
NHL subtypes
 Aggressive B cell NHLb521 (66.4)31.2Ref
 Indolent B cell NHLc59 (7.5)152.40.50 (0.32–0.77)0.001
 T cell NHL27 (3.4)8.31.73 (1.04–2.89)0.03
 NHL–NOS155 (19.7)21.20.97 (0.77–1.22)0.82
 Others23 (2.9)8.31.25 (0.76–2.06)0.36
Calendar period
 1973–1995145 (18.5)10.1Ref
 1996–2000108 (13.8)19.00.90 (0.67–1.21)0.50
 2001–2005196 (25.0)48.90.60 (0.46–0.80)<.001
 2006–2012336 (42.8)60.00.57 (0.44–0.75)<.001
Kaplan–Meier estimate of overall survival by race.
Fig. 3.  Kaplan–Meier estimate of overall survival by race.

Abbreviations: OS, overall survival; 95%CI, confidence interval; aHR, adjusted hazard ratio.

The estimated 5-year OS rates during the periods of 1973–1995, 1996–2000, 2001–2005 and 2006–2012 were 33% (95%CI: 26–41%), 35% (95%CI: 26–44%), 50% (95%CI: 43–57%) and 50% (95%CI: 44–56%), respectively (p < 0.001). The median OS of patients with HEL improved from 19 months when diagnosed in the period of 1996–2000 to 60 months when diagnosed between 2006 and 2012 (p < 0.001) (Table 3, Fig. 4).

Kaplan–Meier estimate of overall survival by calendar year of diagnosis.
Fig. 4.  Kaplan–Meier estimate of overall survival by calendar year of diagnosis.

Abbreviations: OS, overall survival; 95%CI, confidence interval; aHR, adjusted hazard ratio.

The OS rates for the various subtypes of HEL are shown in Table 1 and Fig. 5. The 5-year OS for indolent B cell NHLs was 62% (95%CI: 47–74%), as compared with 44% (95%CI: 39–48%) for aggressive B cell NHLs and 42% (95%CI: 23–60%) for T cell NHLs. The best 5-year OS rates were observed for follicular lymphoma (84%), MZL (60%) and Burkitt’s lymphoma (55%). The 5-year OS of DLBCL was 43%, which was comparable to SLL (42%) and T cell NHL (42%).

Kaplan–Meier estimate of overall survival by cell origin and tumor behavior.
Fig. 5.  Kaplan–Meier estimate of overall survival by cell origin and tumor behavior.

Abbreviations: NHL, non–Hodgkin lymphoma; NOS, not otherwise specified; OS, overall survival; 95%CI, confidence interval; aHR, adjusted hazard ratio.

Table 3 details the multivariable Cox regression analysis of the 785 HEL patients in which age of ≥80 years (aHR: 3.21, p < 0.001), male sex (aHR: 1.26, p = 0.02), Black race (aHR: 1.70, p < 0.001), and T cell NHL histologic subtype (aHR: 1.73, p = 0.03) were unfavorable prognostic factors. The risk of all-cause mortality for patients diagnosed in the periods of 2001–2005 and 2006–2012 were 40% and 43% lower than those diagnosed in the period of 1973–1995 (all, p < 0.001).


PHL is defined according to Caccamo’s criteria34 as lymphoma with only liver involvement at presentation. Although, some have accepted cases as being primary, describing predominant liver involvement, even with the presence of extrahepatic disease.3,29,31

Over a long period of time, I found 785 cases with a first primary NHL of the liver were recorded in the US National Cancer Institute database (1973 to 2012), without a history of prior or concurrent cancer diagnosis. This study represents the largest evaluation of hepatic lymphoma to date. I observed that HEL accounted for 0.25% of all NHLs, which accords with the previous Western6 and Asian reports.25,35 The median age at diagnosis was 61 years (range, 3–95 years), which was slightly older than the literature (50 to 56 years),6,9,29 with a male-to-female ratio of 1.8:1.

DLBCL comprises 33% of all NHL,36 and 46% to 96% of PHL cases.6,9,10,14 Hepatic DLBCL accounted for approximately 6% of all primary extranodal DLBCL.37 My analysis revealed that B cell NHL accounted for approximately 74% all hepatic NHLs, and the most common histopathological diagnosis was DLBCL, which was observed in 496 (63.2%) cases. In a retrospective review of 31 patients with PHL collected from 55 French hospitals, 22 cases (71%) had DLBCL.9 Immunophenotyping analysis of 59 PHL cases; most were of B cell lineage (37 cases, 63%) and 15 were T cell (25%).18

In the current study, the frequency of T-cell NHL is low (3.4%) compared to previous reports (5–10%).3 The most observed hepatic T cell NHLs were mature T cell lymphoma-NOS (59.3%) and anaplastic large cell lymphoma T cell/null cell type (33.3%). In literature, the described subtypes of T cell lymphoma of the liver include peripheral T cell lymphoma,26 anaplastic T cell lymphoma31 and hepatosplenic T cell lymphoma. The frequency of aggressive T cell NHLs increased in Asians (8.7%) and Blacks (6.0%), as compared to Whites (2.8%). This may, in part, reflect increased exposure to pathogenic factors, such as human T cell leukemia virus-1 (HTLV-1) and EBV in Asian and African nations.27,38,39

I observed that the 5-year OS of hepatic DLBCL was 44%, which was comparable to the Japanese report (43%).25 In addition, the risk of mortality for hepatic T cell NHL cases was 73% higher than those with an aggressive B cell NHL of the liver (HR: 1.73, p = 0.03). Notably, many patients with primary hepatic T cell lymphoma present with aggressive diffuse liver infiltration.40

Hepatic marginal zone B cell lymphoma of mucosa-associated lymphoid tissue (MALT) lymphomas are reported to occur in 2–4% of cases of hepatic malignant lymphoma,6,9,29 as a result of chronic antigenic simulation.41 Most PHL in patients with primary biliary cirrhosis is low-grade MALT lymphoma.3 A quarter of primary hepatic MALT lymphomas are HCV sero-positive,25 and spontaneous remission has been reported.9 To date, only 46 cases with primary hepatic MALT lymphoma have been reported and 35.5% had a pre-existing liver disease.30 In the present study, hepatic MZL accounted for about 3% of all cases, with a long 5-year OS (60%) and median OS (82.9 months), comparable to the 84 months reported in 8 primary hepatic MALT lymphoma cases in Japan.25 In a review of 18 hepatic MALT lymphoma cases, median OS was 65 months.25

Follicular lymphoma accounted for less than 4% of PHL.9,29 In our study, the 5-year OS rate of hepatic follicular lymphoma was 84%, which was comparable to the 5-year OS for population of follicular lymphoma (52% to 90%).42 I observed that the hepatic Burkitt’s lymphoma has a slight predominance in females, with 5-year OS of 55% compared to 23% to 71% in a previous report.43 In addition, 40% of deaths in hepatic Burkitt’s lymphoma were related to HIV-related complications. Of note, primary hepatic Burkitt’s lymphoma had been reported in concurrent viral infection, such as HIV,44,45 HCV46 and HBV.47 Anti-HIV therapy has no significant impact on outcomes of HIV-Burkitt’s lymphoma48 compared to some HIV-related lymphomas, such as primary effusion lymphoma.49 In addition, direct-acting antivirals could be promising in HCV-associated indolent B cell NHL.50

In the current study, 474 patients (60.4%) had died by end of study. Of which, 256 patients (54%) died due to NHL, and 80 patients (16.9%) due to HIV-related complications. HIV was reported in 40% to 75% of PHL cases.10,14 In a single centre study, after a median follow-up of 19 months for 22 hepatic lymphoma cases, 12 patients (54.5%) had died.14 Most patients with PHL present with poor prognostic features, such as advanced age, constitutional symptoms, bulky disease, unfavorable histologic subtypes, elevated lactate dehydrogenase, and co-morbidities (cirrhosis, chronic active hepatitis, HIV, immunosuppression, etc.).6,7

Patients with PHL have a favorable survival compared to those with hepatic involvement of systemic lymphoma,25,32 but this issue is controversial.10 In the entire cohort, the median OS was 33 months (95%CI: 21–48 months) and the 5-year OS rate was 44% (95%CI: 41–48%). In the literature, the median survival of PHL cases ranged from 4 to 30 months,6,18,29,51 rising to 60 months in patients who received combined triple-modalities (surgical resection and chemo-radiotherapy).29 The poorest 5-year OS rates were observed for aggressive B cell NHLs (44%, 95%CI: 39–48%) and T cell NHLs (42%, 95%CI: 32–60%). In the Japanese series of 10 PHL cases treated with combined chemotherapy (5 of who received rituximab), the median OS was 27 months, and the 5-year OS rate was 44%.25 The 20-year experience with PHL at the MD Anderson Cancer Center (1974–1995) showed a 5-year OS of 83%.6 The pattern of tumor infiltration had an impact on clinical outcomes.11 In a review of 62 cases, the 3-year OS in nodular PHL was 57%,and in diffuse PHL was 18%,11 versus 49% (95%CI: 46–53%) in our analysis.

In the current study, the mortality risk increased remarkably with advancing age. In addition, the risk of deaths in males was 26% higher than in females (aHR: 1.26, 95%CI: 1.03–1.54). It seems that the poor performance status, rather than advanced age, has negative impact on the outcome of NHL,52 and lymphoma presenting as acute liver failure was seen twice as often in men as it was in women.21 Furthermore, the male predominance is striking in lymphomas of T cell origin.12

I noted that the survival rates were lower in Blacks (aHR: 1.70, p < 0.001) and Asians (aHR: 1.57, p = 0.01) compared with White patients. Notably, Asian patients tended to have aggressive PHL subtypes (i.e. T cell NHL) with diffuse tumor infiltration.51 Furthermore, chronic liver disease before the onset of hepatic lymphoma was reported in 44% of Japanese cases compared to only 9.6% of Western cases.17,53 Regarding the year of diagnosis, the survival improved in the most recent calendar period (2001–2012), and new drugs such as Rituximab may have played a major role.54 Rituximab is an anti-CD20 monoclonal antibody, FDA approved in 1997 for the treatment of relapsed or refractory indolent B cell lymphomas, and then in 2006 approved as a frontline therapy for patients with diffuse large B cell or follicular B cell NHL.

There are several limitations to the present study. The SEER database provides no information regarding whether chemo-immunotherapy was administered. In addition, no data regarding the pattern of liver infiltration and viral status are provided. Although this analysis was restricted, the extranodal NHL affects liver diagnosed by pathology, with no history of prior, or a concurrent cancer diagnosis. Actually, I could not meet the strict criteria for PHL suggested by Caccamo et al.,34 and some cases were not actually PHL, and were cases of secondary liver involvement with extrahepatic disease. However, no standard diagnostic criteria of PHL exist, and some have accepted cases as being primary, describing predominant liver involvement, even with the presence of extrahepatic disease.3,31


In the USA, over a long period of time, first primary NHL of the liver has accounted for about 0.3% of all NHLs. The most common histological variant was DLBCL (63.2%). It appears that the survival of patients with hepatic NHL has improved since 2000. This could reflect the more frequent use of novel agents, such as with rituximab as upfront management of NHLs. Asian and Black patients had more frequent aggressive T cell NHL with poor outcomes, which could be related to an endemic viral infection, such as with HTLV-1 or EBV.



non-Hodgkin lymphoma


primary hepatic lymphoma


human immunodeficiency virus


diffuse large B-cell lymphoma


hepatitis C virus


hepatitis B virus


Epstein–Barr virus


magnetic resonance imaging


overall survival


hepatic lymphoma


marginal zone B cell lymphoma


small B cell lymphocytic lymphoma


human T cell leukemia virus-1


mucosa-associated lymphoid tissue


Conflict of interest

The author has no conflict of interest related to this publication.

Authors’ contributions

Designed the study, performed the data analysis and interpretations, and wrote the manuscript (MAE).


  1. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin’s lymphomas. J Natl Compr Canc Netw 2010;8:288-334 View Article
  2. Krol AD, le Cessie S, Snijder S, Kluin-Nelemans JC, Kluin PM, Noordijk EM. Primary extranodal non-Hodgkin’s lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. Ann Oncol 2003;14:131-139 View Article
  3. Salmon JS, Thompson MA, Arildsen RC, Greer JP. Non-Hodgkin’s lymphoma involving the liver: clinical and therapeutic considerations. Clin Lymphoma Myeloma 2006;6:273-280 View Article
  4. Civardi G, Vallisa D, Bertè R, Lazzaro A, Moroni CF, Cavanna L. Focal liver lesions in non-Hodgkin’s lymphoma: investigation of their prevalence, clinical significance and the role of Hepatitis C virus infection. Eur J Cancer 2002;38:2382-2387 View Article
  5. Aozasa K, Mishima K, Ohsawa M. Primary malignant lymphoma of the liver. Leuk Lymphoma 1993;10:353-357 View Article
  6. Page RD, Romaguera JE, Osborne B, Medeiros LJ, Rodriguez J, North L. Primary hepatic lymphoma: favorable outcome after combination chemotherapy. Cancer 2001;92:2023-2029 View Article
  7. Noronha V, Shafi NQ, Obando JA, Kummar S. Primary non-Hodgkin’s lymphoma of the liver. Crit Rev Oncol Hematol 2005;53:199-207 View Article
  8. Santos ES, Raez LE, Salvatierra J, Morgensztern D, Shanmugan N, Neff GW. Primary hepatic non-Hodgkin’s lymphomas: case report and review of the literature. Am J Gastroenterol 2003;98:2789-2793 View Article
  9. Bronowicki JP, Bineau C, Feugier P, Hermine O, Brousse N, Oberti F. Primary lymphoma of the liver: clinical-pathological features and relationship with HCV infection in French patients. Hepatology 2003;37:781-787 View Article
  10. Swadley MJ, Deliu M, Mosunjac MB, Gunthel CJ, Nguyen ML, Hanley KZ. Primary and secondary hepatic lymphomas diagnosed by image-guided fine-needle aspiration: a retrospective study of clinical and cytomorphologic findings. Am J Clin Pathol 2014;141:119-127 View Article
  11. Emile JF, Azoulay D, Gornet JM, Lopes G, Delvart V, Samuel D. Primary non-Hodgkin’s lymphomas of the liver with nodular and diffuse infiltration patterns have different prognoses. Ann Oncol 2001;12:1005-1010 View Article
  12. Loddenkemper C, Longerich T, Hummel M, Ernestus K, Anagnostopoulos I, Dienes HP. Frequency and diagnostic patterns of lymphomas in liver biopsies with respect to the WHO classification. Virchows Arch 2007;450:493-502 View Article
  13. De Renzo A, Perna F, Persico M, Notaro R, Mainolfi C, de Sio I. Excellent prognosis and prevalence of HCV infection of primary hepatic and splenic non-Hodgkin’s lymphoma. Eur J Haematol 2008;81:51-57 View Article
  14. El-Sharkawi D, Ramsay A, Cwynarski K, Hughes D, Prentice A, Davies N. Clinico-pathologic characteristics of patients with hepatic lymphoma diagnosed using image-guided liver biopsy techniques. Leuk Lymphoma 2011;52:2130-2134 View Article
  15. Kim JH, Kim HY, Kang I, Kim YB, Park CK, Yoo JY. A case of primary hepatic lymphoma with hepatitis C liver cirrhosis. Am J Gastroenterol 2000;95:2377-2380 View Article
  16. Iannitto E, Ammatuna E, Tripodo C, Marino C, Calvaruso G, Florena AM. Long-lasting remission of primary hepatic lymphoma and hepatitis C virus infection achieved by the alpha-interferon treatment. Hematol J 2004;5:530-533 View Article
  17. Higuchi T, Nomoto K, Mori H, Niikura H, Omine M, Sekiyama K. Case report: primary hepatic lymphoma associated with chronic liver disease. J Gastroenterol Hepatol 1997;12:237-242 View Article
  18. Avlonitis VS, Linos D. Primary hepatic lymphoma: a review. Eur J Surg 1999;165:725-729 View Article
  19. Rowbotham D, Wendon J, Williams R. Acute liver failure secondary to hepatic infiltration: a single centre experience of 18 cases. Gut 1998;42:576-580 View Article
  20. Cameron AM, Truty J, Truell J, Lassman C, Zimmerman MA, Kelly BS. Fulminant hepatic failure from primary hepatic lymphoma: successful treatment with orthotopic liver transplantation and chemotherapy. Transplantation 2005;80:993-996 View Article
  21. Lettieri CJ, Berg BW. Clinical features of non-Hodgkins lymphoma presenting with acute liver failure: a report of five cases and review of published experience. Am J Gastroenterol 2003;98:1641-1646 View Article
  22. Seymour JF, Gagel RF, Hagemeister FB, Dimopoulos MA, Cabanillas F. Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin lymphoma. Ann Intern Med 1994;121:633-640 View Article
  23. Maher MM, McDermott SR, Fenlon HM, Conroy D, O’Keane JC, Carney DN. Imaging of primary non-Hodgkin’s lymphoma of the liver. Clin Radiol 2001;56:295-301 View Article
  24. Rizzi EB, Schinina V, Cristofaro M, David V, Bibbolino C. Non-hodgkin’s lymphoma of the liver in patients with AIDS: sonographic, CT, and MRI findings. J Clin Ultrasound 2001;29:125-129 View Article
  25. Kikuma K, Watanabe J, Oshiro Y, Shimogama T, Honda Y, Okamura S. Etiological factors in primary hepatic B-cell lymphoma. Virchows Arch 2012;460:379-387 View Article
  26. Stancu M, Jones D, Vega F, Medeiros LJ. Peripheral T-cell lymphoma arising in the liver. Am J Clin Pathol 2002;118:574-581 View Article
  27. Eom DW, Huh JR, Kang YK, Lee YS, Yu E. Clinicopathological features of eight Korean cases of primary hepatic lymphoma. Pathol Int 2004;54:830-836 View Article
  28. El-Fattah MA. Hepatocellular carcinoma biology predicts survival outcome after liver transplantation in the USA. Indian J Gastroenterol 2017 View Article
  29. Lei KI. Primary non-Hodgkin’s lymphoma of the liver. Leuk Lymphoma 1998;29:293-299 View Article
  30. Murakami J, Fukushima N, Ueno H, Saito T, Watanabe T, Tanosaki R. Primary hepatic low-grade B-cell lymphoma of the mucosa-associated lymphoid tissue type: a case report and review of the literature. Int J Hematol 2002;75:85-90 View Article
  31. Baschinsky DY, Weidner N, Baker PB, Frankel WL. Primary hepatic anaplastic large-cell lymphoma of T-cell phenotype in acquired immunodeficiency syndrome: a report of an autopsy case and review of the literature. Am J Gastroenterol 2001;96:227-232 View Article
  32. Peng Y, Qing AC, Cai J, Yue C, French SW, Qing X. Lymphoma of the liver: Clinicopathological features of 19 patients. Exp Mol Pathol 2016;100:276-280 View Article
  33. O’Neill BP, Decker PA, Tieu C, Cerhan JR. The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin’s lymphoma. Am J Hematol 2013;88:997-1000 View Article
  34. Caccamo D, Pervez NK, Marchevsky A. Primary lymphoma of the liver in the acquired immunodeficiency syndrome. Arch Pathol Lab Med 1986;110:553-555
  35. Ma YJ, Chen EQ, Chen XB, Wang J, Tang H. Primary hepatic diffuse large B cell lymphoma: A case report: Primary hepatic diffuse large B cell lymphoma. Hepat Mon 2011;11:203-205
  36. Møller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation–a population-based study of 1575 cases. Br J Haematol 2004;124:151-159 View Article
  37. López-Guillermo A, Colomo L, Jiménez M, Bosch F, Villamor N, Arenillas L. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 2005;23:2797-2804 View Article
  38. Rizvi MA, Evens AM, Tallman MS, Nelson BP, Rosen ST. T-cell non-Hodgkin lymphoma. Blood 2006;107:1255-1264 View Article
  39. Arisawa K, Soda M, Endo S, Kurokawa K, Katamine S, Shimokawa I. Evaluation of adult T-cell leukemia/lymphoma incidence and its impact on non-Hodgkin lymphoma incidence in southwestern Japan. Int J Cancer 2000;85:319-324 View Article
  40. Miyashita K, Tomita N, Oshiro H, Matsumoto C, Nakajima Y, Ito S. Primary hepatic peripheral T-cell lymphoma treated with corticosteroid. Intern Med 2011;50:617-620 View Article
  41. Ye MQ, Suriawinata A, Black C, Min AD, Strauchen J, Thung SN. Primary hepatic marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type in a patient with primary biliary cirrhosis. Arch Pathol Lab Med 2000;124:604-608 View Article
  42. Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R. Follicular lymphoma international prognostic index. Blood 2004;104:1258-1265 View Article
  43. Smeland S, Blystad AK, Kvaløy SO, Ikonomou IM, Delabie J, Kvalheim G. Treatment of Burkitt’s/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Ann Oncol 2004;15:1072-1078 View Article
  44. Mattar WE, Alex BK, Sherker AH. Primary hepatic burkitt lymphoma presenting with acute liver failure. J Gastrointest Cancer 2010;41:261-263 View Article
  45. Jacobs SL, Rozenblit A. HIV-associated hypervascular primary Burkitt’s lymphoma of the liver. Clin Radiol 2006;61:453-455 View Article
  46. Kuroda J, Omoto A, Fujiki H, Okugawa K, Tamai H, Yamagishi H. Primary hepatic Burkitt’s lymphoma with chronic hepatitis C. Acta Haematol 2001;105:237-240 View Article
  47. Lee SH, Kim HJ, Mun JS, Oh HC, Lee HW, Choi CH. A case of primary hepatic Burkitt’s lymphoma. Korean J Gastroenterol 2008;51:259-264
  48. Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt’s lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol 2005;23:4430-4438 View Article
  49. El-Fattah MA. Clinical characteristics and survival outcome of primary effusion lymphoma: A review of 105 patients. Hematol Oncol 2016 View Article
  50. Arcaini L, Besson C, Frigeni M, Fontaine H, Goldaniga M, Casato M. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood 2016;128:2527-2532 View Article
  51. Lei KI, Chow JH, Johnson PJ. Aggressive primary hepatic lymphoma in Chinese patients. Presentation, pathologic features, and outcome. Cancer 1995;76:1336-1343 View Article
  52. Gómez H, Hidalgo M, Casanova L, Colomer R, Pen DL, Otero J. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin’s lymphoma: results of a multivariate analysis. J Clin Oncol 1998;16:2065-2069 View Article
  53. Ohsawa M, Aozasa K, Horiuchi K, Kataoka M, Hida J, Shimada H. Malignant lymphoma of the liver. Report of five cases and review of the literature. Dig Dis Sci 1992;37:1105-1109 View Article
  54. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242 View Article
  • Journal of Clinical and Translational Hepatology
  • pISSN 2225-0719
  • eISSN 2310-8819
Back to Top

Non-Hodgkin Lymphoma of the Liver: A US Population-based Analysis

Mohamed Abd El-Fattah
  • Reset Zoom
  • Download TIFF